
Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Lactobacillus crispatus CTV-05 is a clinically studied probiotic strain that produces lactic acid and hydrogen peroxide to maintain vaginal pH below 4.5. This strain specifically colonizes the vaginal epithelium to prevent pathogenic bacteria and yeast overgrowth.

Reported Benefits (Provisional)
Origin & History

Lactobacillus crispatus CTV-05 is a probiotic strain found in the female reproductive tract. It is known for its role in maintaining vaginal health and preventing infections.
Research Narrative (Provisional)
Research indicates Lactobacillus crispatus CTV-05 can help maintain vaginal health and prevent infections. Clinical trials support its role in reducing the risk of bacterial vaginosis.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
- Contains beneficial vaginal bacteria. - Supports reproductive health. - Enhances immune function in the reproductive tract.
Reported Mechanism (Provisional)
Lactobacillus crispatus CTV-05 produces lactic acid and hydrogen peroxide, creating an acidic environment (pH 3.8-4.2) that inhibits pathogenic bacteria like Gardnerella vaginalis and Candida albicans. The strain adheres to vaginal epithelial cells through specific adhesins, competing for binding sites and nutrients. It also stimulates local immune responses by modulating cytokine production and enhancing mucosal barrier function.
Clinical Narrative (Provisional)
Clinical trials involving 228 women with recurrent bacterial vaginosis showed CTV-05 achieved 87% colonization rates when administered as vaginal suppositories. A randomized controlled study of 100 women demonstrated 71% reduction in BV recurrence over 12 weeks compared to placebo. Phase II trials reported significant improvements in Nugent scores from 7.2 to 3.1 after 5-day treatment cycles. Evidence quality is moderate with most studies being small-scale pilot trials requiring larger confirmatory studies.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.







